Monthly information on share capital and company voting rights
April 04, 2024 16:30 ET
|
Cellectis Inc.
PARIS, April 04, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...
Monthly information on share capital and company voting rights
March 04, 2024 16:30 ET
|
Cellectis Inc.
PARIS, March 04, 2024 (GLOBE NEWSWIRE) -- (Article 223-16 of General Regulation of the French financial markets authority) Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal...
Monthly information on share capital and company voting rights
February 02, 2024 16:30 ET
|
Cellectis Inc.
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number...
Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology
January 29, 2024 07:00 ET
|
CYTOMED THERAPEUTICS LIMITED
SINGAPORE, Jan. 29, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary...
Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)
January 16, 2024 16:30 ET
|
Cellectis Inc.
NEW YORK, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) (the “Company”), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Monthly information on share capital and company voting rights
January 08, 2024 16:30 ET
|
Cellectis Inc.
PARIS, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...
Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023
December 22, 2023 16:30 ET
|
Cellectis Inc.
NEW YORK, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving...
Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse
December 11, 2023 07:00 ET
|
Marker Therapeutics
HOUSTON, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...
Gallant Therapeutics Announces Launch of JEDI Pivotal Study for First Allogeneic Stem Cell Therapy Targeting Feline Chronic Gingivostomatitis
December 06, 2023 08:19 ET
|
Gallant Therapeutics
Gallant Therapeutics Announces Launch of JEDI Pivotal Study for First Allogeneic Stem Cell Therapy Targeting Feline Chronic Gingivostomatitis
Monthly information on share capital and company voting rights
December 01, 2023 16:30 ET
|
Cellectis Inc.
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 ...